KZA Media Thread, page-668

"new breed of biotech utilising a modern agile approach For funding from inflection point to inflection point whilst and maintaining a flexible approach and pivot points for new trial collaborations?"

That sounds absolutely wonderful and cutting edge but what does it really mean without the buzzwords. In my opinion it means limping from capital raise to capital raise with the resulting dilution and drop in share price